March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Topical Treatment With A Selective COX-2 Inhibitor Promotes Retinal Ganglion Cell Survival After Optic Nerve Crush
Author Affiliations & Notes
  • Oliver W. Gramlich
    Experimental Ophthalmology,
    University Medical Center, Mainz, Mainz, Germany
  • Harald D. von Pein
    Department of Neuropathology,
    University Medical Center, Mainz, Mainz, Germany
  • Anika Ziegler
    Experimental Ophthalmology,
    University Medical Center, Mainz, Mainz, Germany
  • Kathrin Bitz
    Experimental Ophthalmology,
    University Medical Center, Mainz, Mainz, Germany
  • Norbert Pfeiffer
    Experimental Ophthalmology,
    University Medical Center, Mainz, Mainz, Germany
  • Franz H. Grus
    Experimental Ophthalmology,
    University Medical Center, Mainz, Mainz, Germany
  • Footnotes
    Commercial Relationships  Oliver W. Gramlich, None; Harald D. von Pein, None; Anika Ziegler, None; Kathrin Bitz, None; Norbert Pfeiffer, None; Franz H. Grus, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 6273. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Oliver W. Gramlich, Harald D. von Pein, Anika Ziegler, Kathrin Bitz, Norbert Pfeiffer, Franz H. Grus; Topical Treatment With A Selective COX-2 Inhibitor Promotes Retinal Ganglion Cell Survival After Optic Nerve Crush. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6273.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Our previous studies revealed that a selective cyclooxygenase 2 (COX-2) inhibitor promotes neuronal cell survival in cell culture. Now, the study aim was to examine if a COX-2 inhibition with Celecoxib® promotes retinal ganglion cell (RGC) survival after optic nerve crush and could reduce inflammation, especially microglial activation.

Methods: : 30 Lewis rats underwent unilateral optic nerve crush (ONC) under ketamine/xylazine anesthesia. Animals received Celecoxib orally (50mg/kg; n=10) or topically (0.1%, 30 µl; n=10) twice a day. 10 animals served as control with no medical treatment. In five animals per group, neuronal density in the ganglion cell layer was evaluated on cresyl stained retinal flatmounts after ten days. Correspondingly, axon counts of optic nerve sections were performed via toluidine blue staining. In the other five animals per group, cellular infiltrates and optic nerve architecture were examined after H&E and Luxol Fast blue staining in serial horizontal optic nerve sections. Microglia was investigated in detail via anti-Iba 1 immunostaining. Amounts of infiltrates were graded by a 0 (no infiltrates) to 3 (strong infiltration) scoring and microglia was evaluated semi-quantitative.

Results: : No changes in cell and axon density were detected in untreated eyes. At the crushed site, cell and axon density differed not in the oral treated group (1938±372 cells/mm²; 303±83 axons) and the controls with no medication (1922±455 cells/mm²; 278±135 axons). Therefore, the topical treated group showed a significantly increased RGC density and axons (2156±587 cells/mm², p=0.04; 595±161 axons, p<0.001). In this group, the laminar structure of myelin in the optic nerves was predominantly intact and accompanied by a significantly reduction of cell infiltrates (p=0.01). At least, microglial activity was decreased in animals with topical administration.

Conclusions: : A selective COX-2 inhibition reduces infiltration and microglial activity after optic nerve crush and promotes RGC survival. The topical modulation of the cellular immune response by COX-2 inhibition might be a new and sufficient feature for neuroprotection and seems more suitable than a general systemic modulation.

Keywords: optic nerve • neuroprotection • microglia 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×